StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
STOKBullishEarningsnews
High materiality8/10

Stoke targets 2027 rolling NDA for zorevunersen after EMPEROR readout

Aug 3, 2026, 4:03 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Key near-to-mid-term catalysts (EMPEROR readout in 2027, H2 2026 pre-NDA, 2027 rolling NDA) plus a strong cash position support upside potential. Historical biotech trajectories show such regulatory milestones often precede multiple expansion if data are favorable and timelines hold.

AI summary

What happened, with direct paths to the underlying reporting

Stoke Therapeutics reports EMPEROR Phase 3 enrollment completed (162 patients) with readout anticipated in Q3 2027 and a pre-NDA meeting planned for H2 2026. The company also advances STK-002 for ADOA, with initial safety/efficacy data expected in H1 2027. With about $420 million in cash, Stoke aims for U.S. commercialization by early 2028, underpinning a multi-year regulatory path.

  • Phase 3 EMPEROR readout for zorevunersen in Dravet set for Q3 2027.
  • FDA pre-NDA meeting in H2 2026; rolling NDA to begin in Q1 2027.
  • Phase 1/OSPREY STK-002 in ADOA; data expected H1 2027; eight sites active.
  • $420 million cash plus ATM proceeds fund operations through potential U.S. launch by early 2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event